← Leaderboards
George S Laszlo
Fred Hutchinson Cancer Center
$485,634
Attributed
$485,634
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $161.9K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$485,634 · 1
By mechanism
R50$485,634 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Hans-Peter Kiem$98,160,227
- Roland Bruno Walter$12,142,218
- Damian J. Green$13,222,447
- Ajay Gopal$4,782,402
- Frederick R Appelbaum$23,398,619
Others in their field
Other Rising Stars on “Hematopoietic Stem Cells”
- Bruno Di Stefano · Baylor College Of Medicine$4,552,648
- Jennifer Eileen Adair · Fred Hutchinson Cancer Center$3,488,178
- Amy M Moskop · Medical College Of Wisconsin$3,357,500
- Bozena Korczak · Vascular Vision Pharmaceuticals Company$3,058,782
- Andres Hidalgo · Yale University$2,816,555
- Angela Goffredo Fleischman · University Of California-Irvine$2,795,254
Research focus
Hematopoietic Stem CellsAcute Myelocytic LeukemiaAntibodiesHematopoietic NeoplasmsAstatineBench To BedsideBindingBlood CellsAntibody-Drug ConjugatesAcute Myeloid Leukemia CellCellsDistalDoctor Of PhilosophyDrug EfficacyDrug TargetingDrug TestingEffector CellFoundationsGemtuzumab OzogamicinCell LineGenerationsCell PhysiologyGenetically Modified CellsHuman Monoclonal Antibodies
Grant awards (3)
Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders$161,878
R50 · FY2025 · CA · contact PI
Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders$161,878
R50 · FY2024 · CA · contact PI
Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders$161,878
R50 · FY2023 · CA · contact PI